Related Experiment Video
Updated: Jun 22, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Regulatory T cells ameliorate angiotensin II-induced cardiac damage
Heda Kvakan1, Markus Kleinewietfeld, Fatimunnisa Qadri
1Franz Volhard Clinic, HELIOS Clinic Berlin-Buch, Berlin, Germany.
Insights
Regulatory T (Treg) cells protect against hypertensive cardiac damage. Transferring Treg cells improved cardiac structure and function in mice, independent of blood pressure changes, offering new therapeutic avenues.
Area of Science:
- Cardiovascular Research
- Immunology
- Hypertension Pathophysiology
Background:
- Hypertension causes significant morbidity and mortality via target organ damage, particularly cardiac hypertrophy, heart failure, and arrhythmia.
- Angiotensin II, a key mediator in hypertension, promotes inflammation, contributing to cardiac damage.
- The role of immunosuppressive regulatory T (Treg) cells in hypertensive cardiac damage remains largely unexplored.
Purpose of the Study:
- To investigate the protective role of CD4+CD25+ regulatory T (Treg) cells in angiotensin II-induced hypertensive cardiac damage.
- To determine if Treg cell transfer can ameliorate cardiac hypertrophy, fibrosis, and electrical remodeling in a mouse model of hypertension.
Main Methods:
- Adoptive transfer of Treg cells into mice infused with angiotensin II to induce hypertension.
- Assessment of cardiac hypertrophy, fibrosis, and connexin 43 protein localization.
- Analysis of immune cell infiltration in cardiac tissue.
Main Results:
- Treg cell recipients showed reduced cardiac hypertrophy and fibrosis despite sustained hypertension.
- Cardiac morphology improvements correlated with amelioration of arrhythmogenic electrical remodeling.
- Treg cell transfer normalized connexin 43 gap junction protein localization and reduced inflammatory cell infiltration.
Conclusions:
- Transferred Treg cells exert immunosuppressive effects that ameliorate cardiac damage and improve electrical remodeling, independent of blood pressure reduction.
- These findings highlight the critical role of Treg cells in mitigating hypertensive cardiac damage.
- The study suggests potential new therapeutic strategies targeting immune system modulation for treating hypertensive cardiac damage.
Background:
Hypertensive target organ damage, especially cardiac hypertrophy with heart failure and arrhythmia, is a major source of morbidity and mortality. Angiotensin II, a major mediator of hypertension and cardiac damage, has proinflammatory properties. Inflammation and activation of the immune system play a pivotal role in pathogenesis of hypertensive target organ damage. However, the role of immunosuppressive CD4+CD25+ regulatory T (Treg) cells in the pathogenesis of hypertensive target organ damage is unexplored.
Methods And Results:
We conducted adoptive transfer of Treg cells into angiotensin II-infused hypertensive mice. Treg cell recipients exhibited improved cardiac hypertrophy and less cardiac fibrosis despite sustained hypertension. Amelioration of cardiac morphology was accompanied by an improvement in arrhythmogenic electric remodeling, indicating the functional significance of the enhanced cardiac morphology. Delocalization of the connexin 43 gap junction protein is one of the major pathomechanisms in electric remodeling. Pronounced connexin 43 immunoreactivity was found at the lateral borders of cardiomyocytes in angiotensin II-treated mice. In contrast, connexin 43 was restricted to the intercalated disk regions in sham controls. Surprisingly, angiotensin II+Treg-treated mice showed normal connexin 43 gap junction protein localization. Adoptive Treg cell transfer resulted in a marked reduction in cardiac CD4+, CD8+, and CD69+ cell and macrophage infiltration.
Conclusions:
Immunosuppressive effects of transferred Treg cells ameliorated cardiac damage and accounted for the improved electric remodeling independently of blood pressure-lowering effects. Our results provide new insights into the pathogenesis of hypertensive cardiac damage and could therefore lead to new therapeutic approaches that involve manipulation of the immune system.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure II: Pathophysiology
Hypertension II: Pathophysiology